Comparative Pharmacology
Head-to-head clinical analysis: KEFTAB versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFTAB versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
KEFTAB vs ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
None Documented
None Documented
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic